Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer maintains an Overweight rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $50 to $60.
August 08, 2024 | 2:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer maintains an Overweight rating on Mirum Pharmaceuticals and raises the price target from $50 to $60.
The raised price target and maintained Overweight rating from a reputable analyst are likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100